ArticleMolecular therapy. Advances2026
Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fragile skin may benefit from decoration.Molecular therapy. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a skin and epithelial fragility disease that progresses with severe fibrosis. This fibrosis is debilitating and promotes the development of aggressive squamous cell carcinomas (SCCs). Effective management of fibrosis may improve quality of life in RDEB and reduce the risk of high-risk SCCs. Decorin, a small leucine-rich proteoglycan, has natural fibrosis-limiting activity. Higher expression of decorin has been linked to milder RDEB, and decorin has shown anti-fibrotic effects in multiple models of experimentally induced fibrosis. However, a short circulating half-life, manufacturing challenges, and broad target engagement have limited the development of systemic decorin therapy. Here, we describe scalable production of recombinant human decorin protein core (rh Decorin) and test repeated intravenous administration in a murine model of advanced RDEB. We show that rh Decorin accumulates in the skin and other injured sites and improves RDEB-related signs. Systemic administration enables decorin-mediated direct and indirect inhibition of TGF-β activity in peripheral tissues. Characterization of the dermal collagen matrix revealed evidence of remodeling capacity of fibrotic lesions in RDEB when cellular contractile activities are targeted, providing an explanation for the anti-fibrotic effects of rh Decorin in advanced disease. These results support further evaluation of intravenous rh Decorin for the treatment of RDEB, especially for fibrotic manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.